Mylan NV recently announced the launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene’s Vidaza® Injection, 100 mg/vial.
Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
Mylan’s launch of this product adds to the company’s portfolio of more than 150 injectable products available to patients in the US across a broad array of therapeutic categories. Azacitidine for Injection is also a part of a growing US portfolio of more than 20 oncology medications that includes treatments for breast, lung, colorectal, ovarian and hematologic cancers.
